Suppr超能文献

为精准剂量给药辩护:可视化重症成人中头孢吡肟暴露的变异性。

Making the case for precision dosing: visualizing the variability of cefepime exposures in critically ill adults.

机构信息

Department of Pharmacy Practice, Midwestern University College of Pharmacy, 555 31st St., Downers Grove, IL 60515, USA.

Midwestern University College of Pharmacy, Pharmacometrics Center of Excellence, Downers Grove, IL, USA.

出版信息

J Antimicrob Chemother. 2023 Sep 5;78(9):2170-2174. doi: 10.1093/jac/dkad211.

Abstract

OBJECTIVE

To investigate and describe the variability in cefepime exposures among 'real-world', critically ill patients by using population pharmacokinetic modelling and simulations, and with translation of these findings to visualizations.

METHODS

A cohort of adult medical ICU patients who received cefepime with therapeutic drug monitoring was studied. Two compartment models were developed to estimate cefepime clearance (Model 1) and simulate cefepime exposures among 1000 patients, each with identical creatinine clearance of 60 mL/min and receiving a regimen of cefepime 1 gram IV over 30 minutes, every 8 hours (Model 2). Variability in the relationship between cefepime clearance and creatinine clearance (CrCL) was visualized, and a random, representative sample of 10 simulated patients was utilized to illustrate variability in cefepime exposures.

RESULTS

A total of 75 adult medical ICU patients (52% female) and 98 serum cefepime samples were included in the study. Population parameter estimates for cefepime displayed a wide range of variation in Model 1 (CV: 45% to 95%), with low bias at the individual level at 0.226 mg/L but high bias in the population model 10.6 mg/L. Model 2 displayed similar fits, demonstrating that correcting for individual patient creatinine clearance slightly improves the bias of the population model (bias = 4.31 mg/L). Among 10 simulated patients that a clinician would deem similar from a dosing perspective (i.e. equivalent creatinine clearance), maximum concentrations after three simulated doses varied more than 8-fold from 41.2 to 339 mg/L at the 5th and 95th percentiles, and clearance profiles were highly different.

CONCLUSION

Creatinine clearance estimates alone are inadequate for predicting cefepime exposures. Wide variations in cefepime exposure exist among ICU patients, even for those with similar kidney function estimates. Current population adjustment schemes based solely on creatinine clearance will result in unintended high and low exposures leading to safety and efficacy concerns, respectively.

摘要

目的

通过群体药代动力学建模和模拟,研究并描述真实世界中重症监护病房(ICU)危重症患者中头孢吡肟的暴露变异性,并将这些发现转化为可视化结果。

方法

本研究纳入了接受头孢吡肟治疗药物监测的成年 ICU 患者队列。建立了两个房室模型来估计头孢吡肟清除率(模型 1),并模拟 1000 名患者的头孢吡肟暴露情况,每位患者的肌酐清除率均为 60mL/min,接受头孢吡肟 1 克静脉输注 30 分钟,每 8 小时一次(模型 2)。可视化头孢吡肟清除率与肌酐清除率(CrCL)之间的关系变异性,并利用 10 名模拟患者的随机代表性样本来说明头孢吡肟暴露的变异性。

结果

本研究共纳入 75 名成年 ICU 患者(52%为女性)和 98 份血清头孢吡肟样本。模型 1 中的头孢吡肟群体参数估计值显示出广泛的变异性(变异系数:45%至 95%),个体水平的低偏差为 0.226mg/L,但群体模型的高偏差为 10.6mg/L。模型 2 显示出相似的拟合度,表明校正个体患者的肌酐清除率略微改善了群体模型的偏差(偏差=4.31mg/L)。在 10 名模拟患者中,从给药角度来看,临床医生认为他们相似(即等效肌酐清除率),在第 5 和 95 百分位数时,三次模拟剂量后的最大浓度从 41.2 至 339mg/L 变化超过 8 倍,清除曲线也存在显著差异。

结论

仅肌酐清除率估计不足以预测头孢吡肟的暴露。即使对于肾功能估计相似的 ICU 患者,头孢吡肟的暴露也存在广泛的变异性。目前基于肌酐清除率的群体调整方案将导致意外的高暴露和低暴露,分别导致安全性和疗效问题。

相似文献

引用本文的文献

1
Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis.治疗药物监测在耐多药结核病治疗中的作用
J Clin Tuberc Other Mycobact Dis. 2024 Apr 24;36:100444. doi: 10.1016/j.jctube.2024.100444. eCollection 2024 Aug.

本文引用的文献

1
Cefepime-induced neurotoxicity: systematic review.头孢吡肟致神经毒性:系统评价。
J Antimicrob Chemother. 2022 Oct 28;77(11):2908-2921. doi: 10.1093/jac/dkac271.
2
Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.头孢吡肟的临床药代动力学和药效学。
Clin Pharmacokinet. 2022 Jul;61(7):929-953. doi: 10.1007/s40262-022-01137-y. Epub 2022 Jun 29.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验